Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 6Completed 6Withdrawn 2Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 41Other solid neoplasm 3Dermatologic 3Other hematologic neoplasm 2Lymphoid 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Triple Negative Breast Neoplasms 2

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Leucovorin × Breast × Clear all
NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡